Patents Assigned to Amgen
  • Human CGRP receptor binding proteins
    Patent number: 9862771
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 9, 2018
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Growth differentiation factor 15 (GDF-15) constructs
    Patent number: 9862752
    Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: January 9, 2018
    Assignee: Amgen Inc.
    Inventors: Yumei Xiong, Yi Zhang, Jackie Z. Sheng, Agnes Eva Hamburger, Murielle Veniant-Ellison, Grant Shimamoto, Xiaoshan Min, Zhulun Wang, Jie Tang, Gunasekaran Kannan, Marissa Mock, Kenneth Walker
  • METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
    Publication number: 20180002733
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Application
    Filed: July 17, 2017
    Publication date: January 4, 2018
    Applicant: Amgen Inc.
    Inventors: Jian WU, Sean DAVERN, Simina Crina PETROVAN, Michael Charles BRANDENSTEIN, Katherine Rose LINDAHL, Shawn Erik LILLIE
  • Refolding proteins using a chemically controlled redox state
    Patent number: 9856287
    Abstract: A method of refolding proteins expressed in non-mammalian cells present in concentrations of 2.0 g/L or higher is disclosed. The method comprises identifying the thiol pair ratio and the redox buffer strength to achieve conditions under which efficient folding at concentrations of 2.0 g/L or higher is achieved and can be employed over a range of volumes, including commercial scale.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: January 2, 2018
    Assignee: Amgen Inc.
    Inventors: Joseph Edward Shultz, Roger Hart, Ronald Nixon Keener, III
  • Processes of making and crystalline forms of a MDM2 inhibitor
    Patent number: 9855259
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: January 2, 2018
    Assignee: Amgen Inc.
    Inventors: Matthew Bio, Sebastien Caille, Brian Cochran, Yuanqing Fang, Filisaty Vounatsos, Sarah Wortman
  • DRUG DELIVERY DEVICE WITH LIVE BUTTON OR USER INTERFACE FIELD
    Publication number: 20170368260
    Abstract: A drug delivery device includes a container for storing a drug, the container having a stopper for expelling the drug; an injection drive comprising an energy source for directly or indirectly acting on the stopper to expel the drug; a sensor for detecting contact between the drug delivery device and a body of a patient; and a user interface (UI) for activating or causing the activation of the injection drive. The device is operative for drawing attention to the UI, if the sensor detects contact between the drug delivery device and the body of the patient, to thereby indicate that the injection drive is ready to be activated, which activation is the next step in the drug administration process.
    Type: Application
    Filed: December 10, 2015
    Publication date: December 28, 2017
    Applicant: AMGEN INC.
    Inventors: Adam B. McCullough, Scott R. Gibson
  • FEED MEDIA
    Publication number: 20170369837
    Abstract: The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.
    Type: Application
    Filed: August 8, 2017
    Publication date: December 28, 2017
    Applicant: AMGEN INC.
    Inventors: Arvia Eleanor MORRIS, Aurora Villegas VIAJE, Erika PINEDA
  • Secreted frizzle-related protein 5 (SFRP5) binding proteins
    Patent number: 9850297
    Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the SFRP5 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 26, 2017
    Assignee: Amgen Inc.
    Inventors: Jiangwen Majeti, YuMei Xiong, Wen-Chen Yeh, Alykhan S. Motani, Yang Li
  • Stable Frozen Virus Formulation
    Publication number: 20170360857
    Abstract: A live virus composition that maintains infectivity and provides improved virus stability during one or more freeze/thaw cycles and/or during long term storage in a liquid state at temperatures ranging from just above freezing to ambient temperatures.
    Type: Application
    Filed: December 15, 2015
    Publication date: December 21, 2017
    Applicant: AMGEN INC.
    Inventors: Jennifer R. LITOWSKI, Christine Claudia SISKA, Bruce Arthur KERWIN
  • PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN
    Publication number: 20170362625
    Abstract: The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
    Type: Application
    Filed: December 1, 2015
    Publication date: December 21, 2017
    Applicant: AMGEN INC.
    Inventors: Daniel R. LEISKE, Michael T. TRENTALANGE
  • Intermediates for preparing triazole agonists of the APJ receptor
    Patent number: 9845310
    Abstract: Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: December 19, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Simon J. Hedley
  • Production Of Glycoproteins Using Manganese
    Publication number: 20170355741
    Abstract: Culture media comprising manganese and methods of culturing cells to improve sialylation and glycosylation of glycoproteins are provided.
    Type: Application
    Filed: August 22, 2017
    Publication date: December 14, 2017
    Applicant: AMGEN INC.
    Inventors: Christopher Kenyon CROWELL, Gustavo Enrique GRAMPP
  • Methods and apparati for nondestructive detection of undissolved particles in a fluid
    Patent number: 9842408
    Abstract: The apparati, methods, and computer program products disclosed herein can be used to nondestructively detect undissolved particles, such as glass flakes and/or protein aggregates, in a fluid in a vessel, such as, but not limited to, a fluid that contains a drug.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: December 12, 2017
    Assignee: AMGEN INC.
    Inventors: Graham F. Milne, Erwin Freund, Ryan L. Smith
  • Lyophilized formulation comprising GM-CSF neutralizing compound
    Patent number: 9833410
    Abstract: The present invention relates to aqueous formulations comprising at least 20 mg/ml of a compound neutralizing GM-CSF, a lyoprotectant and an amino acid and/or a buffer. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of lyophilization, storage and reconstruction. In a preferred aspect, the formulation, e.g. after reconstruction, is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: December 5, 2017
    Assignees: Takeda GmbH, Amgen Research (Munich) GmbH
    Inventors: Markus Rast, Wolfram Steinhilber, Christian de Muynck, Gerhard Becker, Pernille Dybendal Pedersen, Thomas Urbig, Thomas Boehm
  • METHODS AND COMPOSITIONS RELATING TO ANTI-CCR7 ANTIGEN BINDING PROTEINS
    Publication number: 20170342155
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
    Type: Application
    Filed: July 31, 2017
    Publication date: November 30, 2017
    Applicant: AMGEN INC.
    Inventors: Chadwick Terence KING, Gordon NG, Shaw-Fen Sylvia HU, Hung NGUYEN, Jeannie JUNG
  • REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS
    Publication number: 20170333559
    Abstract: A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl proline and mixtures thereof in combination with a therapeutiv protein. A stable pharmaceutical formulation is also provided.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 23, 2017
    Applicant: AMGEN INC.
    Inventors: Christopher James SLOEY, Sekhar KANAPURAM
  • Methods for increasing mannose content of recombinant proteins
    Patent number: 9822388
    Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 21, 2017
    Assignee: Amgen Inc.
    Inventors: Jian Wu, Sean Davern, Simina Crina Petrovan, Michael Charles Brandenstein, Katherine Rose Lindahl, Shawn Erik Lillie
  • Stable liquid formulation of AMG 416 (etelcalcetide)
    Patent number: 9820938
    Abstract: A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: November 21, 2017
    Assignee: Amgen Inc.
    Inventors: Derek Maclean, Qun Yin
  • Heterodimeric immunoglobulins
    Patent number: 9822173
    Abstract: The present application is directed to heterodimeric antibodies and methods of use.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: November 21, 2017
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Monica Florio, Zhi Liu, Wei Yan
  • Human PAC1 antibodies
    Patent number: 9822178
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: November 21, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger